NovaBridge Biosciences (FRA:0VY)
Germany flag Germany · Delayed Price · Currency is EUR
1.630
+0.020 (1.24%)
At close: Aug 26, 2026

NovaBridge Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.63-1.5513.86
Revenue Growth
------94.14%
Gross Profit
---0.63-1.556.55
Operating Income
-122.63-94.27-51.43-48.98-53.08-326.06
Net Income
-117.55-88.34-22.23-207.73-371.05-367.02
Earnings Per Share
-1.04-0.92-0.27-2.50-4.50-4.83
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
190.85210.84173.4311.73500.78673.24
Total Debt
4.463.073.883.8910.8717.7
Net Cash (Debt)
186.39207.78169.52307.84489.91655.53
Net Cash Growth
14.96%22.57%-44.93%-37.16%-25.26%-10.41%
Net Cash Per Share
1.652.172.093.705.948.63

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-45.68-20.6-106.63-146.5-90.22-153.18
Capital Expenditures
-0.99-0.01-0.05-0.16-2.09-4.71
Free Cash Flow
-46.67-20.6-106.68-146.66-92.32-157.89
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---100.00%-47.25%
Operating Margin
----7749.37%--2353.06%
Pretax Margin
----13009.02%9097.36%-2652.28%
Profit Margin
----32868.51%--2648.70%
FCF Margin
----23206.33%--1139.46%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---249.50-223.95263.21